Compendium of Cancer Genome Aberrations

Changes

Germline Cancer Predisposition Genes (view source)

Revision as of 21:17, 8 February 2016

460 bytes added ,  21:17, 8 February 2016
no edit summary
Line 7: Line 7:  
|[[ALK]]||2p23||[[familial neuroblastoma]]||[[neuroblastoma]]
 
|[[ALK]]||2p23||[[familial neuroblastoma]]||[[neuroblastoma]]
 
|-
 
|-
−
|[[APC]]||5q21||[[adenomatous polyposis coli; Turcot syndrome]]||[[colorectal, pancreatic, desmoid, hepatoblastoma, glioma, other CNS]]
+
|[[APC]]||5q21||[[adenomatous polyposis coli; Turcot syndrome]]||[[colorectal]],[[ pancreatic]],[[ desmoid]],[[ hepatoblastoma]],[[ glioma]],[[ other CNS]]
 
|-
 
|-
−
|[[ATM]]||11q22.3||[[ataxia-telangiectasia]]||[[leukaemia, lymphoma, medulloblastoma, glioma]]
+
|[[ATM]]||11q22.3||[[ataxia-telangiectasia]]||[[leukaemia]],[[ lymphoma]],[[ medulloblastoma]],[[ glioma]]
 
|-
 
|-
 
|[[ATR]]||3q23||[[familial cutaneous telangiectasia and cancer sydrome]]||[[oropharyngeal]]
 
|[[ATR]]||3q23||[[familial cutaneous telangiectasia and cancer sydrome]]||[[oropharyngeal]]
Line 15: Line 15:  
|[[AXIN2]]||17q24.1||[[oligodontia-colorectal cancer syndrome]]||[[colorectal carcinoma]]
 
|[[AXIN2]]||17q24.1||[[oligodontia-colorectal cancer syndrome]]||[[colorectal carcinoma]]
 
|-
 
|-
−
|[[BAP1]]||3p21.31-p21.2|| ||[[mesothelioma, uveal melanoma]]
+
|[[BAP1]]||3p21.31-p21.2|| ||[[mesothelioma]],[[ uveal melanoma]]
 
|-
 
|-
−
|[[BLM]]||15q26.1||[[Bloom syndrome]]||[[leukaemia, lymphoma, skin squamous cell, other tumour types]]
+
|[[BLM]]||15q26.1||[[Bloom syndrome]]||[[leukaemia]],[[ lymphoma]],[[ skin squamous cell]],[[ other tumour types]]
 
|-
 
|-
 
|[[BMPR1A]]||10q22.3||[[juvenile polyposis]]||[[gastrointestinal polyps]]
 
|[[BMPR1A]]||10q22.3||[[juvenile polyposis]]||[[gastrointestinal polyps]]
 
|-
 
|-
−
|[[BRCA1]]||17q21||[[hereditary breast/ovarian cancer]]||[[breast, ovarian]]
+
|[[BRCA1]]||17q21||[[hereditary breast/ovarian cancer]]||[[breast]],[[ ovarian]]
 
|-
 
|-
−
|[[BRCA2]]||13q12||[[hereditary breast/ovarian cancer]]||[[breast, ovarian, pancreatic, leukaemia  (FANCB, FANCD1)]]
+
|[[BRCA2]]||13q12||[[hereditary breast/ovarian cancer]]||[[breast]],[[ ovarian]],[[ pancreatic]],[[ leukaemia  (FANCB]],[[ FANCD1)]]
 
|-
 
|-
−
|[[BRIP1]]||17q22||[[Fanconi anaemia J, breast cancer susceptiblity]]||[[AML, leukaemia, breast]]
+
|[[BRIP1]]||17q22||[[Fanconi anaemia J]],[[ breast cancer susceptiblity]]||[[AML]],[[ leukaemia]],[[ breast]]
 
|-
 
|-
 
|[[BUB1B]]||15q15||[[mosaic variegated aneuploidy]]||[[rhabdomyosarcoma]]
 
|[[BUB1B]]||15q15||[[mosaic variegated aneuploidy]]||[[rhabdomyosarcoma]]
 
|-
 
|-
−
|[[CDC73]]||1q21-q31||[[hyperparathyroidism-jaw tumour syndrome]]||[[parathyroid adenoma, multiple ossifying jaw fibroma]]
+
|[[CDC73]]||1q21-q31||[[hyperparathyroidism-jaw tumour syndrome]]||[[parathyroid adenoma]],[[ multiple ossifying jaw fibroma]]
 
|-
 
|-
 
|[[CDH1]]||16q22.1||[[familial gastric carcinoma]]||[[gastric]]
 
|[[CDH1]]||16q22.1||[[familial gastric carcinoma]]||[[gastric]]
Line 35: Line 35:  
|[[CDK4]]||12q14||[[familial malignant melanoma]]||[[melanoma]]
 
|[[CDK4]]||12q14||[[familial malignant melanoma]]||[[melanoma]]
 
|-
 
|-
−
|[[CDKN1B]]||12p13.1-p12||[[multiple endocrine neoplasia type IV]]||[[pituitary, parathyroid]]
+
|[[CDKN1B]]||12p13.1-p12||[[multiple endocrine neoplasia type IV]]||[[pituitary]],[[ parathyroid]]
 
|-
 
|-
−
|[[CDKN2A]]||9p21||[[familial malignant melanoma]]||[[melanoma, pancreatic]]
+
|[[CDKN2A]]||9p21||[[familial malignant melanoma]]||[[melanoma]],[[ pancreatic]]
 
|-
 
|-
 
|[[CHEK2]]||22q12.1||[[familial breast cancer]]||[[breast]]
 
|[[CHEK2]]||22q12.1||[[familial breast cancer]]||[[breast]]
Line 43: Line 43:  
|[[CYLD]]||16q12-q13||[[familial cylindromatosis]]||[[cylindroma]]
 
|[[CYLD]]||16q12-q13||[[familial cylindromatosis]]||[[cylindroma]]
 
|-
 
|-
−
|[[DDB2]]||11p12||[[xeroderma pigmentosum (E)]]||[[skin basal cell, skin squamous cell, melanoma]]
+
|[[DDB2]]||11p12||[[xeroderma pigmentosum (E)]]||[[skin basal cell]],[[ skin squamous cell]],[[ melanoma]]
 
|-
 
|-
 
|[[DICER1]]||14q32.13||[[familial pleuropulmonary blastoma or DICER1 syndrome]]||[[pleuropulmonary blastoma]]
 
|[[DICER1]]||14q32.13||[[familial pleuropulmonary blastoma or DICER1 syndrome]]||[[pleuropulmonary blastoma]]
Line 49: Line 49:  
|[[EGFR]]||7p12.3-p12.1||[[familial lung cancer]]||[[NSCLC]]
 
|[[EGFR]]||7p12.3-p12.1||[[familial lung cancer]]||[[NSCLC]]
 
|-
 
|-
−
|[[ERCC2]]||19q13.2-q13.3||[[xeroderma pigmentosum (D)]]||[[skin basal cell, skin squamous cell, melanoma]]
+
|[[ERCC2]]||19q13.2-q13.3||[[xeroderma pigmentosum (D)]]||[[skin basal cell]],[[ skin squamous cell]],[[ melanoma]]
 
|-
 
|-
−
|[[ERCC3]]||2q21||[[xeroderma pigmentosum (B)]]||[[skin basal cell, skin squamous cell, melanoma]]
+
|[[ERCC3]]||2q21||[[xeroderma pigmentosum (B)]]||[[skin basal cell]],[[ skin squamous cell]],[[ melanoma]]
 
|-
 
|-
−
|[[ERCC4]]||16p13.3-p13.13||[[xeroderma pigmentosum (F)]]||[[skin basal cell, skin squamous cell, melanoma]]
+
|[[ERCC4]]||16p13.3-p13.13||[[xeroderma pigmentosum (F)]]||[[skin basal cell]],[[ skin squamous cell]],[[ melanoma]]
 
|-
 
|-
−
|[[ERCC5]]||13q33||[[xeroderma pigmentosum (G)]]||[[skin basal cell, skin squamous cell, melanoma]]
+
|[[ERCC5]]||13q33||[[xeroderma pigmentosum (G)]]||[[skin basal cell]],[[ skin squamous cell]],[[ melanoma]]
 
|-
 
|-
−
|[[EXT1]]||8q24.11-q24.13||[[multiple exostoses type 1]]||[[exostoses, osteosarcoma]]
+
|[[EXT1]]||8q24.11-q24.13||[[multiple exostoses type 1]]||[[exostoses]],[[ osteosarcoma]]
 
|-
 
|-
−
|[[EXT2]]||11p12-p11||[[multiple exostoses type 2]]||[[exostoses, osteosarcoma]]
+
|[[EXT2]]||11p12-p11||[[multiple exostoses type 2]]||[[exostoses]],[[ osteosarcoma]]
 
|-
 
|-
−
|[[FANCA]]||16q24.3||[[Fanconi anaemia A]]||[[AML, leukaemia]]
+
|[[FANCA]]||16q24.3||[[Fanconi anaemia A]]||[[AML]],[[ leukaemia]]
 
|-
 
|-
−
|[[FANCC]]||9q22.3||[[Fanconi anaemia C]]||[[AML, leukaemia]]
+
|[[FANCC]]||9q22.3||[[Fanconi anaemia C]]||[[AML]],[[ leukaemia]]
 
|-
 
|-
−
|[[FANCD2]]||3p26||[[Fanconi anaemia D2]]||[[AML, leukaemia]]
+
|[[FANCD2]]||3p26||[[Fanconi anaemia D2]]||[[AML]],[[ leukaemia]]
 
|-
 
|-
−
|[[FANCE]]||6p21-p22||[[Fanconi anaemia E]]||[[AML, leukaemia]]
+
|[[FANCE]]||6p21-p22||[[Fanconi anaemia E]]||[[AML]],[[ leukaemia]]
 
|-
 
|-
−
|[[FANCF]]||11p15||[[Fanconi anaemia F]]||[[AML, leukaemia]]
+
|[[FANCF]]||11p15||[[Fanconi anaemia F]]||[[AML]],[[ leukaemia]]
 
|-
 
|-
−
|[[FANCG]]||9p13||[[Fanconi anaemia G]]||[[AML, leukaemia]]
+
|[[FANCG]]||9p13||[[Fanconi anaemia G]]||[[AML]],[[ leukaemia]]
 
|-
 
|-
−
|[[FH]]||1q42.1||[[hereditary leiomyomatosis and renal cell cancer]]||[[leiomyomatosis, renal]]
+
|[[FH]]||1q42.1||[[hereditary leiomyomatosis and renal cell cancer]]||[[leiomyomatosis]],[[ renal]]
 
|-
 
|-
−
|[[FLCN]]||17p11.2||[[Birt-Hogg-Dube syndrome]]||[[renal, fibrofolliculomas, trichodiscomas]]
+
|[[FLCN]]||17p11.2||[[Birt-Hogg-Dube syndrome]]||[[renal]],[[ fibrofolliculomas]],[[ trichodiscomas]]
 
|-
 
|-
 
|[[GPC3]]||Xq26.1||[[Simpson-Golabi-Behmel syndrome]]||[[Wilms tumour]]
 
|[[GPC3]]||Xq26.1||[[Simpson-Golabi-Behmel syndrome]]||[[Wilms tumour]]
 
|-
 
|-
−
|[[HNF1A]]||12q24.2||[[familial hepatic adenoma]]||[[hepatic adenoma, hepatocellular carcinoma]]
+
|[[HNF1A]]||12q24.2||[[familial hepatic adenoma]]||[[hepatic adenoma]],[[ hepatocellular carcinoma]]
 
|-
 
|-
−
|[[HRAS]]||11p15.5||[[Costello syndrome]]||[[rhabdomyosarcoma, ganglioneuroblastoma, bladder]]
+
|[[HRAS]]||11p15.5||[[Costello syndrome]]||[[rhabdomyosarcoma]],[[ ganglioneuroblastoma]],[[ bladder]]
 
|-
 
|-
−
|[[KIT]]||4q12||[[familial gastrointestinal stromal tumour]]||[[GIST, epithelioma]]
+
|[[KIT]]||4q12||[[familial gastrointestinal stromal tumour]]||[[GIST]],[[ epithelioma]]
 
|-
 
|-
 
|[[LMO1]]||11p15|| ||[[neuroblastoma]]
 
|[[LMO1]]||11p15|| ||[[neuroblastoma]]
Line 89: Line 89:  
|[[MAX]]||14q23|| ||[[pheochromocytoma]]
 
|[[MAX]]||14q23|| ||[[pheochromocytoma]]
 
|-
 
|-
−
|[[MEN1]]||11q13||[[multiple endocrine neoplasia type 1]]||[[parathyroid adenoma, pituitary adenoma, pancreatic islet cell, carcinoid]]
+
|[[MEN1]]||11q13||[[multiple endocrine neoplasia type 1]]||[[parathyroid adenoma]],[[ pituitary adenoma]],[[ pancreatic islet cell]],[[ carcinoid]]
 
|-
 
|-
−
|[[MLH1]]||3p21.3||[[hereditary non-polyposis colorectal cancer, Turcot syndrome]]||[[colorectal, endometrial, ovarian, CNS]]
+
|[[MLH1]]||3p21.3||[[hereditary non-polyposis colorectal cancer]],[[ Turcot syndrome]]||[[colorectal]],[[ endometrial]],[[ ovarian]],[[ CNS]]
 
|-
 
|-
 
|[[MPL]]||1p34||[[familial essential thrombocythemia]]||[[MPN]]
 
|[[MPL]]||1p34||[[familial essential thrombocythemia]]||[[MPN]]
 
|-
 
|-
−
|[[MSH2]]||2p22-p21||[[hereditary non-polyposis colorectal cancer]]||[[colorectal, endometrial, ovarian]]
+
|[[MSH2]]||2p22-p21||[[hereditary non-polyposis colorectal cancer]]||[[colorectal]],[[ endometrial]],[[ ovarian]]
 
|-
 
|-
−
|[[MSH6]]||2p16||[[hereditary non-polyposis colorectal cancer]]||[[colorectal, endometrial, ovarian]]
+
|[[MSH6]]||2p16||[[hereditary non-polyposis colorectal cancer]]||[[colorectal]],[[ endometrial]],[[ ovarian]]
 
|-
 
|-
 
|[[MUTYH]]||1p34.3-1p32.1||[[adenomatous polyposis coli]]||[[colorectal]]
 
|[[MUTYH]]||1p34.3-1p32.1||[[adenomatous polyposis coli]]||[[colorectal]]
 
|-
 
|-
−
|[[NBN]]||8q21||[[Nijmegen breakage syndrome]]||[[NHL, glioma, medulloblastoma, rhabdomyosarcoma]]
+
|[[NBN]]||8q21||[[Nijmegen breakage syndrome]]||[[NHL]],[[ glioma]],[[ medulloblastoma]],[[ rhabdomyosarcoma]]
 
|-
 
|-
−
|[[NF1]]||17q12||[[neurofibromatosis type 1]]||[[neurofibroma, glioma]]
+
|[[NF1]]||17q12||[[neurofibromatosis type 1]]||[[neurofibroma]],[[ glioma]]
 
|-
 
|-
−
|[[NF2]]||22q12.2||[[neurofibromatosis type 2]]||[[meningioma, acoustic neuroma]]
+
|[[NF2]]||22q12.2||[[neurofibromatosis type 2]]||[[meningioma]],[[ acoustic neuroma]]
 
|-
 
|-
−
|[[PALB2]]||16p12.1||[[Fanconi anaemia N, breast cancer susceptibility]]||[[Wilms tumour, medulloblastoma, AML ,breast]]
+
|[[PALB2]]||16p12.1||[[Fanconi anaemia N]],[[ breast cancer susceptibility]]||[[Wilms tumour]],[[ medulloblastoma]],[[ AML ]],[[breast]]
 
|-
 
|-
 
|[[PDGFRA]]||4q11-q13||[[familial gastrointestinal stromal tumour]]||[[GIST]]
 
|[[PDGFRA]]||4q11-q13||[[familial gastrointestinal stromal tumour]]||[[GIST]]
Line 113: Line 113:  
|[[PHOX2B]]||4p12||[[familial neuroblastoma]]||[[neuroblastoma]]
 
|[[PHOX2B]]||4p12||[[familial neuroblastoma]]||[[neuroblastoma]]
 
|-
 
|-
−
|[[PMS1]]||2q31-q33||[[hereditary non-polyposis colorectal cancer]]||[[colorectal, endometrial, ovarian]]
+
|[[PMS1]]||2q31-q33||[[hereditary non-polyposis colorectal cancer]]||[[colorectal]],[[ endometrial]],[[ ovarian]]
 
|-
 
|-
−
|[[PMS2]]||7p22||[[hereditary non-polyposis colorectal cancer, Turcot syndrome]]||[[colorectal, endometrial, ovarian, medulloblastoma, glioma]]
+
|[[PMS2]]||7p22||[[hereditary non-polyposis colorectal cancer]],[[ Turcot syndrome]]||[[colorectal]],[[ endometrial]],[[ ovarian]],[[ medulloblastoma]],[[ glioma]]
 
|-
 
|-
 
|[[POLE]]||12q24.3|| ||[[colorectal cancer susceptibility]]
 
|[[POLE]]||12q24.3|| ||[[colorectal cancer susceptibility]]
 
|-
 
|-
−
|[[PRF1]]||10q22|| ||[[various leukaemia, lymphoma]]
+
|[[PRF1]]||10q22|| ||[[various leukaemia]],[[ lymphoma]]
 
|-
 
|-
−
|[[PRKAR1A]]||17q23-q24||[[Carney complex]]||[[myxoma, endocrine, papillary thyroid]]
+
|[[PRKAR1A]]||17q23-q24||[[Carney complex]]||[[myxoma]],[[ endocrine]],[[ papillary thyroid]]
 
|-
 
|-
−
|[[PTCH1]]||9q22.3||[[nevoid basal cell carcinoma syndrome]]||[[skin basal cell, medulloblastoma]]
+
|[[PTCH1]]||9q22.3||[[nevoid basal cell carcinoma syndrome]]||[[skin basal cell]],[[ medulloblastoma]]
 
|-
 
|-
−
|[[PTEN]]||10q23.3||[[Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome]]||[[harmartoma, glioma, prostate, endometrial]]
+
|[[PTEN]]||10q23.3||[[Cowden syndrome]],[[ Bannayan-Riley-Ruvalcaba syndrome]]||[[harmartoma]],[[ glioma]],[[ prostate]],[[ endometrial]]
 
|-
 
|-
−
|[[RB1]]||13q14||[[familial retinoblastoma]]||[[retinoblastoma, sarcoma, breast, small cell lung carcinoma]]
+
|[[RB1]]||13q14||[[familial retinoblastoma]]||[[retinoblastoma]],[[ sarcoma]],[[ breast]],[[ small cell lung carcinoma]]
 
|-
 
|-
−
|[[RECQL4]]||8q24.3||[[Rothmund-Thompson syndrome]]||[[osteosarcoma, skin basal cell, skin sqamous cell]]
+
|[[RECQL4]]||8q24.3||[[Rothmund-Thompson syndrome]]||[[osteosarcoma]],[[ skin basal cell]],[[ skin sqamous cell]]
 
|-
 
|-
−
|[[RET]]||10q11.2||[[multiple endocrine neoplasia 2A/2B]]||[[medullary thyroid,  papillary thyroid, pheochromocytoma]]
+
|[[RET]]||10q11.2||[[multiple endocrine neoplasia 2A/2B]]||[[medullary thyroid]],[[ papillary thyroid]],[[ pheochromocytoma]]
 
|-
 
|-
−
|[[SBDS]]||7q11||[[Schwachman-Diamond syndrome]]||[[AML, MDS]]
+
|[[SBDS]]||7q11||[[Schwachman-Diamond syndrome]]||[[AML]],[[ MDS]]
 
|-
 
|-
 
|[[SDHAF2]]||11q12.2||[[familial paraganglioma]]||[[paraganglioma]]
 
|[[SDHAF2]]||11q12.2||[[familial paraganglioma]]||[[paraganglioma]]
 
|-
 
|-
−
|[[SDHB]]||1p36.1-p35||[[familial paraganglioma]]||[[paraganglioma, pheochromocytoma]]
+
|[[SDHB]]||1p36.1-p35||[[familial paraganglioma]]||[[paraganglioma]],[[ pheochromocytoma]]
 
|-
 
|-
−
|[[SDHC]]||1q21||[[familial paraganglioma]]||[[paraganglioma, pheochromocytoma]]
+
|[[SDHC]]||1q21||[[familial paraganglioma]]||[[paraganglioma]],[[ pheochromocytoma]]
 
|-
 
|-
−
|[[SDHD]]||11q23||[[familial paraganglioma]]||[[paraganglioma, pheochromocytoma]]
+
|[[SDHD]]||11q23||[[familial paraganglioma]]||[[paraganglioma]],[[ pheochromocytoma]]
 
|-
 
|-
 
|[[SETBP1]]||18q21.1||[[Schinzel-Giedion syndrome]]||[[neuroepithelial tumours]]
 
|[[SETBP1]]||18q21.1||[[Schinzel-Giedion syndrome]]||[[neuroepithelial tumours]]
Line 153: Line 153:  
|[[STAT3]]||17q21.31|| ||[[paediatric large granular lymphocytic leukaemia]]
 
|[[STAT3]]||17q21.31|| ||[[paediatric large granular lymphocytic leukaemia]]
 
|-
 
|-
−
|[[STK11]]||19p13.3||[[Peutz-Jeghers syndrome]]||[[jejunal hamartoma, ovarian, testicular, pancreatic]]
+
|[[STK11]]||19p13.3||[[Peutz-Jeghers syndrome]]||[[jejunal hamartoma]],[[ ovarian]],[[ testicular]],[[ pancreatic]]
 
|-
 
|-
 
|[[SUFU]]||10q24.32||[[medulloblastoma predisposition]]||[[medulloblastoma]]
 
|[[SUFU]]||10q24.32||[[medulloblastoma predisposition]]||[[medulloblastoma]]
Line 159: Line 159:  
|[[TERT]]||5p15.33|| ||[[melanoma]]
 
|[[TERT]]||5p15.33|| ||[[melanoma]]
 
|-
 
|-
−
|[[TP53]]||17p13||[[Li-Fraumeni syndrome]]||[[breast, sarcoma, adrenocortical carcinoma, glioma, multiple other tumour types]]
+
|[[TP53]]||17p13||[[Li-Fraumeni syndrome]]||[[breast]],[[ sarcoma]],[[ adrenocortical carcinoma]],[[ glioma]],[[ multiple other tumour types]]
 
|-
 
|-
−
|[[TSC1]]||9q34||[[Tuberous sclerosis 1]]||[[hamartoma, renal cell carcinoma, tuberous sclerosis tuber]]
+
|[[TSC1]]||9q34||[[Tuberous sclerosis 1]]||[[hamartoma]],[[ renal cell carcinoma]],[[ tuberous sclerosis tuber]]
 
|-
 
|-
−
|[[TSC2]]||16p13.3||[[Tuberous sclerosis 2]]||[[hamartoma, renal cell carcinoma, tuberous sclerosis tuber]]
+
|[[TSC2]]||16p13.3||[[Tuberous sclerosis 2]]||[[hamartoma]],[[ renal cell carcinoma]],[[ tuberous sclerosis tuber]]
 
|-
 
|-
 
|[[TSHR]]||14q31|| ||[[thyroid adenoma]]
 
|[[TSHR]]||14q31|| ||[[thyroid adenoma]]
 
|-
 
|-
−
|[[VHL]]||3p25||[[Von Hippel-Lindau syndrome]]||[[renal, haemangioma, pheochromocytoma]]
+
|[[VHL]]||3p25||[[Von Hippel-Lindau syndrome]]||[[renal]],[[ haemangioma]],[[ pheochromocytoma]]
 
|-
 
|-
 
|[[WAS]]||Xp11.23-p11.22||[[Wiskott-Aldrich syndrome]]||[[lymphoma]]
 
|[[WAS]]||Xp11.23-p11.22||[[Wiskott-Aldrich syndrome]]||[[lymphoma]]
 
|-
 
|-
−
|[[WRN]]||8p12-p11.2||[[Werner syndrome]]||[[osteosarcoma, meningioma, other tumour types]]
+
|[[WRN]]||8p12-p11.2||[[Werner syndrome]]||[[osteosarcoma]],[[ meningioma]],[[ other tumour types]]
 
|-
 
|-
−
|[[WT1]]||11p13||[[Denys-Drash syndrome, Frasier syndrome, familial Wilms tumour]]||[[Wilms tumour]]
+
|[[WT1]]||11p13||[[Denys-Drash syndrome]],[[ Frasier syndrome]],[[ familial Wilms tumour]]||[[Wilms tumour]]
 
|-
 
|-
−
|[[XPA]]||9q22.3||[[xeroderma pigmentosum (A)]]||[[skin basal cell, skin squamous cell, melanoma]]
+
|[[XPA]]||9q22.3||[[xeroderma pigmentosum (A)]]||[[skin basal cell]],[[ skin squamous cell]],[[ melanoma]]
 
|-
 
|-
−
|[[XPC]]||3p25||[[xeroderma pigmentosum (C)]]||[[skin basal cell, skin squamous cell, melanoma]]
+
|[[XPC]]||3p25||[[xeroderma pigmentosum (C)]]||[[skin basal cell]],[[ skin squamous cell]],[[ melanoma]]
       
|}
 
|}
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/162"